Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.
The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.
MRI in patients with pacemakers or implantable cardioverter-defibrillators (March 2017)
Potential risks of magnetic resonance imaging (MRI) in patients with permanent pacemakers or implantable cardioverter-defibrillators (ICDs) include programming changes, pacing abnormalities, and induced currents in lead wires. In a prospective multicenter trial, 1500 nonthoracic MRI examinations were performed in a 1.5T magnet on patients with a non-MRI-conditional pacemaker or ICD that had been programmed according to a standardized protocol; no device or lead failures were observed . While these reports are reassuring, the presence of a pacemaker or ICD is still generally considered a strong relative contraindication to routine MRI. (See "Principles of magnetic resonance imaging", section on 'Permanent pacemakers and implantable cardioverter-defibrillators'.)
Risk of sudden cardiac death in patients with HCM and LV apical aneurysms (February 2017)
Patients with hypertrophic cardiomyopathy (HCM) have an increased risk of death from several causes, including ventricular tachycardia (VT) resulting in sudden cardiac death (SCD). Clinical evaluation for five established major risk factors (ie, syncope, nonsustained VT, massive left ventricular hypertrophy, abnormal blood pressure response to exercise, and family history of SCD) helps to identify patients for whom an implantable cardioverter defibrillator (ICD) may be warranted for primary prevention of SCD. A recent paper supports an additional criterion for ICD placement . In this study, patients with HCM and a left ventricular (LV) apical aneurysm, compared with patients without an LV apical aneurysm, had five times the risk of VT and SCD. Patients with HCM and an LV apical aneurysm should receive strong consideration for ICD placement, as well as radiofrequency ablation for recurrent VT, if present. (See "Hypertrophic cardiomyopathy: Assessment and management of ventricular arrhythmias and sudden cardiac death risk", section on 'Established high-risk clinical features'.)
Emergency coronary catheterization following sudden cardiac arrest (February 2017)
Emergency coronary catheterization is indicated for patients who sustain sudden cardiac arrest (SCA) and manifest signs of an acute coronary syndrome (ACS), such as ST elevation on their electrocardiogram. However, whether coronary catheterization should be performed in SCA patients without such signs remains controversial. A meta-analysis of 11 heterogeneous, retrospective studies involving several thousand patients found that over 30 percent of post-arrest patients with no ST elevation had acute coronary artery occlusions regardless of their presenting rhythm . While randomized trials are needed to address this question, we believe it is reasonable to perform coronary catheterization in SCA patients without discrete signs of ACS, provided resources to do so are available. (See "Post-cardiac arrest management in adults", section on 'Coronary revascularization'.)
Dabigatran combined with certain statins associated with increased risk of major bleeding (February 2017)
An analysis of health records of nearly 46,000 Canadian patients showed that older adults (age ≥66) with atrial fibrillation taking dabigatran who also received simvastatin or lovastatin had approximately a 50 percent greater risk of hospitalization for major hemorrhage relative to those who used other statins . Although the mechanism for this interaction is uncertain, until additional information becomes available, it may be prudent to choose a statin other than lovastatin or simvastatin for older patients receiving dabigatran, and for those with an elevated risk for serious bleeding. (See "Statins: Actions, side effects, and administration", section on 'Drug interactions'.)
Late gadolinium enhancement to risk stratify patients for primary prevention ICD placement (January 2017)
Late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) imaging appears to reflect myocardial fibrosis, which has been proposed as a pathogenic factor for ventricular arrhythmias. Risk stratification remains imperfect for identifying patients at highest risk of sudden cardiac death (SCD) who are most likely to benefit from an implantable cardioverter-defibrillator (ICD).
●A systematic review and meta-analysis of 29 observational studies in patients with nonischemic dilated cardiomyopathy assessed the relationship between LGE on CMR imaging and ventricular arrhythmias, sustained ventricular arrhythmias . Appropriate ICD intervention or sudden cardiac death (SCD) was significantly more likely in patients with LGE, with subgroup analysis revealing that LGE risk stratified patients at all levels of left ventricular ejection fraction (LVEF) (both above and below 35 percent).
●In a meta-analysis, which included 2993 patients with hypertrophic cardiomyopathy from five cohorts, the presence of LGE on CMR imaging was associated with greater risk for total mortality, cardiovascular mortality, and SCD .
While not currently utilized in SCD risk stratification schemes , when the risk of SCD remains uncertain after assessment with conventional risk factors, LGE may help to guide decision-making with regard to implantation of a defibrillator for primary prevention of SCD. (See "Primary prevention of sudden cardiac death in heart failure and cardiomyopathy", section on 'Myocardial fibrosis on CMR' and "Hypertrophic cardiomyopathy: Assessment and management of ventricular arrhythmias and sudden cardiac death risk", section on 'Possible high-risk features'.)
Comparison of complications and efficacy between subcutaneous and transvenous ICDs (December 2016)
Transvenous implantable cardioverter-defibrillators (TV-ICDs) are associated with several complications related to the reliance on endovascular leads. The subcutaneous ICD (S-ICD) was developed to minimize some of the limitations of TV-ICD systems by avoiding endovascular access entirely. In a retrospective cohort study which propensity-matched S-ICD and TV-ICD recipients, the overall complication rate and efficacy was similar between the two groups . S-ICD recipients experienced fewer lead-related complications but more nonlead-related complications, with a similar frequency of ICD shocks (both appropriate and inappropriate) between the two groups. While there are no defined guidelines for the selection of S-ICD over a TV-ICD system, our approach in deciding between the two for a specific patient is based on several clinical variables (algorithm 1). (See "Subcutaneous implantable cardioverter defibrillators", section on 'Comparison with TV-ICD'.)
CONGENITAL HEART DISEASE, ADULT
Risk factors for mortality in Eisenmenger syndrome (December 2016)
Eisenmenger syndrome consists of the triad of congenital systemic-to-pulmonary cardiovascular communication, pulmonary arterial disease caused by increased pulmonary blood flow, and cyanosis. This syndrome is associated with high mortality rates but limited data are available on predictors of death in a contemporary population. In a multicenter study of 1098 patients with Eisenmenger syndrome followed for a median of three years, significant predictors of death on multivariable analysis included older age, presence of a pre-tricuspid shunt, lower oxygen saturation at rest, lack of sinus rhythm, and presence of pericardial effusion . (See "Evaluation and prognosis of Eisenmenger syndrome", section on 'Prognosis'.)
CORONARY ARTERY BYPASS GRAFT SURGERY
Multiple rather than single arterial grafts in patients undergoing CABG (December 2016)
There is conflicting evidence as to whether survival is improved with placement of multiple arterial grafts, rather than one, in patients undergoing coronary artery bypass graft surgery (CABG). The 2016 ART trial, which randomly assigned 3102 patients scheduled to undergo CABG to bilateral or single internal thoracic artery grafting, found no significant difference in the rate of death at five years. . Based on findings from earlier studies, and the relatively short-term follow-up of the ART trial, we consider placing multiple arterial grafts in patients with a predicted longevity of more than 10 years who are not at high risk of sternal wound infection (which occurs more frequently with multiple arterial grafts). (See "Coronary artery bypass graft surgery: Long-term clinical outcomes", section on 'Multiple arterial grafts'.)
CORONARY HEART DISEASE, ACUTE
Rapid aspirin desensitization in patients with acute coronary syndrome (April 2017)
There are well-established protocols for elective desensitization to aspirin, but fewer studies of approaches in patients needing urgent treatment. In a multicenter observational study of 330 consecutive patients with acute coronary syndrome and past hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs), 95 percent were successfully desensitized to low-dose aspirin using a protocol that could be completed within six hours . The procedure was aborted in 5 percent because symptoms developed during the protocol. While useful, we prefer our own approach because it does not exclude patients who react during the protocol. (See "Diagnostic challenge and desensitization protocols for NSAID reactions", section on 'Our approach'.)
Trimethylamine-N-oxide (TMAO) levels and prognosis in patients with acute coronary syndrome (April 2017)
Trimethylamine-N-oxide (TMAO), produced through intestinal microbial metabolism of dietary lecithin, appears to contribute to the development of atherosclerosis. Elevated TMAO levels may be of prognostic significance as well. In a cohort of 530 consecutive patients with suspected acute coronary syndrome (ACS), elevated TMAO levels at presentation were associated with greater risk of major adverse cardiac events (myocardial infarction, stroke, revascularization, and death) at 30 days and six months and an increased risk of mortality at seven years . TMAO levels vary significantly according to diet as well as kidney and liver function, so additional studies are needed to confirm their role as a prognostic marker in patients with ACS. (See "Overview of possible risk factors for cardiovascular disease", section on 'Trimethylamine-N-oxide (TMAO)'.)
Complete revascularization for STEMI patients undergoing primary PCI (February 2017, Modified April 2017)
Several studies have evaluated the management of significant nonculprit coronary lesions in patients with ST-elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI).
●The Compare-Acute trial randomly assigned 885 patients to undergo complete revascularization of noninfarct-related coronary arteries or no revascularization . Fractional flow reserve (FFR) was measured in both groups and nonculprit PCI was usually performed within minutes of primary PCI in the revascularization group. The primary composite end point (death from any cause, nonfatal MI, (repeat) revascularization, and cerebrovascular events at 12 months) occurred less often with complete revascularization, driven principally by many fewer revascularizations.
●A 2017 network meta-analysis, published before Compare-Acute, compared four revascularization strategies: complete revascularization at the index procedure; complete revascularization prior to discharge; complete revascularization within a few weeks after discharge; and culprit-only PCI . Major adverse cardiovascular events occurred less frequently in patients who underwent complete revascularization, performed at any of the time intervals, compared with culprit-only PCI. The outcome was mainly attributable to a lower rate of urgent revascularization.
These studies support our suggestion to perform FFR-guided PCI of nonculprit lesions prior to discharge in most cases and to do so at the time of primary PCI in many. (See "Primary percutaneous coronary intervention in acute ST-elevation myocardial infarction: Non-culprit lesions", section on 'Management approaches to non-culprit lesions'.)
Switching MI patients from ticagrelor to clopidogrel (March 2017)
The potent platelet P2Y12 receptor blocker ticagrelor, rather than clopidogrel, is initiated in hospital for many patients with myocardial infarction. However, some of these individuals will need to switch to clopidogrel either before or after hospital discharge. A randomized trial compared the pharmacodynamic effects of switching from ticagrelor to clopidogrel with or without a loading dose of clopidogrel . The study identified a period of time after the first dose of clopidogrel (12 hours after the last dose of ticagrelor) when there was greater antiplatelet effect with the loading dose than without. Based on this pharmacodynamic study, we give a clopidogrel loading dose of 600 mg when switching from ticagrelor to clopidogrel therapy. (See "Antiplatelet agents in acute ST elevation myocardial infarction", section on 'Switching from a P2Y12 agent to clopidogrel' and "Antiplatelet agents in acute non-ST elevation acute coronary syndromes", section on 'Switching from a P2Y12 agent to clopidogrel'.)
CORONARY HEART DISEASE, STABLE
Fluctuations in body weight and risk of CHD (April 2017)
While obesity is associated with an increased risk for coronary heart disease (CHD) and sustained weight loss reduces the risk of CHD, the effects of frequent weight gain and loss on CHD risk are unknown. A post hoc analysis of data from a secondary prevention statin study involving over 9000 patients with established CHD and LDL cholesterol below 130 mg/dL (3.4 mmol/L) found that patients in the highest quintile of weight fluctuation (mean variability of 3.9 kg) had significantly higher risks of any CHD event, any cardiovascular disease event, and total mortality, compared with those in the quintile with the lowest weight variation, and that risk increased with each standard deviation change in magnitude of weight fluctuation . These findings suggest that frequent cycles of weight gain and weight loss are associated with an increased risk of CHD and cardiovascular disease events, with greatest magnitude of risk among those who were overweight or obese at baseline. (See "Overview of the risk equivalents and established risk factors for cardiovascular disease", section on 'Obesity'.)
Rivaroxaban plus P2Y12 inhibitor in patients with atrial fibrillation who undergo coronary stenting (March 2017)
The optimal antithrombotic regimen for patients with atrial fibrillation (AF) who undergo coronary artery stenting is not known. Patients may require a period of triple antithrombotic therapy with an oral anticoagulant, aspirin, and a P2Y12 inhibitor (usually clopidogrel). In most of the studies that have evaluated triple therapy, warfarin was the anticoagulant rather than a non-vitamin K antagonist oral anticoagulant. In addition, bleeding complications have led to the evaluation of antithrombotic therapy with two agents. The PIONEER AF-PCI trial compared three regimens in over 2000 patients: low-dose rivaroxaban plus a P2Y12 inhibitor for 12 months; very-low-dose rivaroxaban plus dual antiplatelet therapy (DAPT); or standard therapy with a dose-adjusted vitamin K antagonist plus DAPT . Clinically significant bleeding occurred less often in the two groups receiving rivaroxaban; efficacy was similar in the three groups at 12 months. This study supports the use of rivaroxaban as a reasonable alternative to warfarin, and the use of two rather than three drugs in patients who are candidates for triple therapy. The very-low-dose of rivaroxaban used in the trial is not approved for use in this setting. (See "Antithrombotic therapy after coronary stenting in patients receiving long-term anticoagulation", section on 'Alternatives to warfarin'.)
Ularitide does not improve outcomes for acute heart failure (May 2017)
Early vasodilator therapy has been proposed as a means of improving outcomes for acute heart failure. However, in a randomized trial comparing a 48-hour infusion of ularitide (a synthetic analogue of the renal vasodilatory peptide urodilatin) with placebo in over 2000 patients presenting with acute heart failure, ularitide led to greater reductions in systolic blood pressure but no difference in clinical outcomes at 48 hours based upon a composite endpoint . Cardiovascular mortality rates at 15 months were similar for both groups. Thus, ularitide caused short-term hemodynamic effects but did not improve clinical outcomes. (See "Treatment of acute decompensated heart failure: Components of therapy", section on 'Ularitide'.)
Adaptive servoventilation in adults with central sleep apnea and heart failure (April 2017)
A previous randomized trial (SERVE-HF) found that adaptive servoventilation (ASV), a modified method of positive airway pressure ventilation, increased cardiovascular mortality in patients with central sleep apnea (CSA) due to symptomatic heart failure with reduced ejection fraction. In the CAT-HF trial, 126 hospitalized patients with heart failure and moderate-to-severe CSA were randomly assigned to ASV plus optimized medical therapy or medical therapy alone . While the trial showed no difference between the groups in a combined endpoint (death, cardiovascular hospitalizations, and timed walk distance), the confidence intervals were wide and there was a suggestion of increased harm in the ASV group (HR 1.06, 95% CI 0.75-1.51). The trial was stopped early, in part due to results of SERVE-HF. Although this limits interpretation of the CAT-HF results, we continue to recommend against use of ASV in patients with CSA and heart failure with reduced ejection fraction. (See "Sleep-disordered breathing in heart failure", section on 'Adaptive servoventilation' and "Central sleep apnea: Treatment", section on 'Patients with ejection fraction ≤45 percent'.)
Targeting natriuretic peptide level in treatment of acute heart failure (February 2017)
Since natriuretic peptides have relatively short half-lives, it has been postulated that serial measurements might help guide management of acute heart failure. A systematic review found low-quality evidence supporting an association between achievement of natriuretic predischarge thresholds and reduced acute heart failure mortality and readmission . However, a randomized trial studying the effect of treating to a target natriuretic peptide level found no improvement in outcomes with a natriuretic peptide-guided strategy, although a reduction in natriuretic peptide during hospitalization was associated with better outcomes [20,21]. Thus, natriuretic peptide levels have prognostic value in patients with acute heart failure, but evidence does not support targeting lower levels as a means of improving outcomes. (See "Natriuretic peptide measurement in heart failure", section on 'Acute HF'.)
Methamphetamine use and cardiomyopathy (June 2017)
Cardiovascular complications, particularly cardiomyopathy, are the leading causes of death among individuals using methamphetamine, yet there are few data on cardiomyopathy outcomes among methamphetamine users. In a study of 30 methamphetamine users with reduced left ventricular ejection fraction (LVEF) who were followed for a mean of nearly three years, cessation of use compared with continuing use was associated with better cardiac function and a trend toward reduced cardiac symptoms . The extent of myocardial fibrosis was associated with the duration of methamphetamine use and may serve as a marker of irreversible ventricular changes. (See "Methamphetamine use disorder: Epidemiology, clinical manifestations, course, assessment, and diagnosis", section on 'Cardiovascular disease'.)
Risk of thromboembolism in patients with HCM and LV apical aneurysm (February 2017)
Although subsets of patients with hypertrophic cardiomyopathy (HCM) and a risk factor for thromboembolism (eg, atrial fibrillation, left ventricular [LV] aneurysm) are at high risk for thromboembolic events, they have generally been excluded from studies of thromboembolism prophylaxis. Among a cohort of patients with HCM and LV apical aneurysm who were in normal sinus rhythm, the thromboembolic event rate without anticoagulation exceeded 1 percent per year, regardless of the size of the aneurysm . For patients with HCM and LV apical aneurysm, we suggest long-term oral anticoagulation, rather than aspirin or no anticoagulation, to reduce the risk of thromboembolism. (See "Hypertrophic cardiomyopathy: Medical therapy", section on 'Thromboembolism prophylaxis'.)
PERIPHERAL VASCULAR DISEASE
Ticagrelor versus clopidogrel for prevention of cardiovascular events in patients with peripheral artery disease (January 2017)
Antiplatelet therapy is recommended for patients with peripheral artery disease (PAD) to prevent future cardiovascular events. The EUCLID trial randomly assigned nearly 14,000 patients with symptomatic PAD to ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily . The clopidogrel group had less ischemic stroke (1.9 versus 2.4 percent), but there were no significant differences between groups for the composite primary outcome (cardiovascular death, myocardial infarction [MI], or ischemic stroke) or for death, MI, acute limb ischemia, need for revascularization, or major bleeding. Patients receiving ticagrelor were more likely to discontinue treatment due to dyspnea or minor bleeding. These data support the use of clopidogrel rather than ticagrelor as an alternative to aspirin for patients with PAD. (See "Overview of lower extremity peripheral artery disease", section on 'Antithrombotic therapy'.)
Long-term follow-up of percutaneous femoropopliteal angioplasty for claudication (January 2017)
Whether minimally invasive vascular intervention improves the clinical status of patients with claudication due to peripheral artery disease (PAD) is debated. The early outcomes of a trial comparing femoropopliteal percutaneous transluminal angioplasty (PTA), a supervised exercise program (SEP), or combined treatment (PTA + SEP) found combined treatment produced a greater improvement in some clinical outcome measures than PTA or SEP alone. However, longer-term follow-up (mean 5.2 years) is now available and showed no significant differences between the groups for observed treadmill walking distances, restenosis rates, or quality-of-life outcomes . These results support our recommendation to treat claudication with a medical therapy regimen that includes risk factor modification and exercise therapy (and possibly pharmacologic therapy), rather than any form of vascular intervention. (See "Management of claudication", section on 'Initial therapy'.)
Small interfering RNA molecules to lower PCSK9 and LDL-C (April 2017)
The profound ability of monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9) to lower low-density lipoprotein-cholesterol (LDL-C) has prompted research into other ways of lowering PCSK9. Small interfering RNA molecules (siRNA) offer the potential to lower PCSK9 at a decreased dose frequency compared with monoclonal antibodies. One siRNA inhibitor of PCSK9 synthesis (inclisiran) has undergone phase 2 (dose-finding) evaluation. A randomized trial compared several doses of inclisiran with placebo in 501 patients at high cardiovascular disease risk receiving maximal possible dose of statin therapy . At the highest dose, inclisiran reduced LDL-C by approximately 50 percent from baseline and there were no serious adverse events. (See "PCSK9 inhibitors: Pharmacology, adverse effects, and use", section on 'Ongoing investigation'.)
PCSK9 antibody therapy in patients with cardiovascular disease (April 2017)
While it has been known for a number of years that PCSK9 antibodies lower low-density lipoprotein cholesterol (LDL-C) by as much as 60 percent, long-term clinical outcomes have not been published. In the FOURIER trial, over 27,000 patients with cardiovascular disease (CVD) were randomly assigned to receive evolocumab or placebo in addition to moderate or high-intensity statin therapy . After a median follow-up of 2.2 years, patients treated with evolocumab had a lower risk of non-fatal myocardial infarction and non-fatal stroke, but no decrease in CVD mortality or all-cause mortality. The results of FOURIER strengthen our suggestion to use this class of drug in selected patients (eg, those with an acute coronary syndrome or high-risk patients with stable coronary disease). (See "Intensity of lipid lowering therapy in secondary prevention of cardiovascular disease", section on 'Stable CHD'.)
ACE inhibitors or ARBs not routinely indicated in low-risk patients with stable ischemic heart disease (January 2017)
Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs), referred to as renin angiotensin system inhibitors (RASi), improve survival in high-risk patients with stable ischemic heart disease (SIHD), such as those with heart failure or diabetes. However, a 2017 meta-analysis of 24 randomized trials of RASi compared with placebo or to active control in patients with SIHD without clinical heart failure and with a left ventricular ejection fraction ≥40 percent found that benefit was not present in patients enrolled in studies in which the cardiovascular event rates were low . We do not routinely prescribe RASi to patients with SIHD at low risk of adverse cardiovascular events. (See "Prevention of cardiovascular disease events in those with established disease or at high risk", section on 'ACE inhibitors or ARBs'.)
Role of troponin testing in primary prevention (January 2017)
Across a broad range of populations, elevated troponin is associated with an increased risk of cardiovascular disease (CVD) events. In the primary prevention West of Scotland Coronary Prevention Study of individuals at high CVD risk who were randomly assigned to either statin or placebo, individuals in the highest quartile of high-sensitivity troponin were at the greatest risk of a CVD event at one year in both treated and untreated individuals . Studies designed to evaluate the role of troponin testing in patients being considered for statin therapy or in those started on statin therapy are ongoing. (See "Elevated cardiac troponin concentration in the absence of an acute coronary syndrome", section on 'Elevations in patients at high risk'.)
Risk calculator for estimating cardiovascular disease risk in Chinese patients (January 2017)
A number of multivariate risk models have been developed for estimating the risk of initial cardiovascular disease (CVD) events in apparently healthy, asymptomatic individuals. The Predication for ASCVD Risk in China (China-PAR) project published a risk score which was developed and prospectively validated in two Chinese cohort groups . China-PAR, the first risk estimator specific to Chinese populations, more accurately predicted the risk of future CVD events for Chinese patients than the ACC/AHA pooled cohort equations, which were developed and validated in North American populations. While all risk models have advantages and disadvantages and no single risk model is appropriate for all patients, clinicians should choose a risk calculator which is most appropriate based on the gender and ethnicity of the patient. (See "Estimation of cardiovascular risk in an individual patient without known cardiovascular disease", section on 'China-PAR risk predictor (2016)'.)
Instantaneous wave-free ratio versus fractional flow reserve for coronary artery stenosis evaluation (May 2017)
For patients with coronary artery stenoses of intermediate severity, measurement of fractional flow reserve (FFR) with adenosine-induced hyperemia may be used to assess the functional significance of the lesion. However, patients often complain of significant chest pain, attributable to the adenosine, which limits its use. Two randomized non-inferiority trials have compared clinical outcomes for low-risk patients evaluated by FFR with a newer method, instantaneous wave-free ratio (iFR), which does not require adenosine [30,31]. The rate of a composite clinical outcome (death, myocardial infarction, or unplanned revascularization within 12 months) was similar in both groups, but the frequency of adenosine-induced chest discomfort was less with iFR and the duration of the procedure was shorter. We choose either iFR or FFR for evaluation of intermediate lesions. (See "Clinical use of coronary artery pressure flow measurements", section on 'iFR compared with FFR'.)
Increased risk of stent thrombosis with bioresorbable intracoronary scaffolds (April 2017)
Bioresorbable intracoronary stents were developed to overcome limitations of metallic intracoronary stents, such as the inability to subsequently place a bypass graft. However, early trials of these new stents have suggested an increased risk of stent thrombosis compared with commonly used drug-eluting stents. In a preliminary analysis of the AIDA trial, which randomly assigned over 1800 patients to a bioresorbable or metallic stent, there was an increased risk of definite or probable device thrombosis in the scaffold group at two years and there was no evidence of benefit . We do not advocate the routine use of bioresorbable intracoronary drug-eluting stents. (See "Bioresorbable polymer or scaffold drug-eluting coronary artery stents", section on 'Bioresorbable stents or scaffolds'.)
VALVULAR HEART DISEASE
Embolic protection devices during transcatheter aortic valve implantation (April 2017)
Transcatheter aortic valve implantation (TAVI) has an evolving role as an alternative to surgical aortic valve replacement in treating patients with symptomatic severe aortic stenosis. However, TAVI is associated with an increased risk of stroke and risk of subclinical ischemic brain lesions on magnetic resonance imaging (MRI). Embolic protection devices (EPDs) have been studied as potential means of reducing this risk of stroke. A meta-analysis included 16 studies involving 1170 patients who underwent TAVI, the majority treated with EPD . Analyses comparing EPD versus no EPD strategies could not confirm or exclude differences in clinically evident stroke or mortality at 30 days. While there was no significant difference in numbers of new lesions, use of EPD was associated with a significantly smaller total volume of ischemic lesions. Further study is needed to determine whether EPDs can improve clinical outcomes. (See "Transcatheter aortic valve implantation: Complications", section on 'Stroke and subclinical brain injury'.)
Subclinical bioprosthetic leaflet thrombosis (March 2017)
The prevalence and clinical significance of subclinical leaflet thrombosis of bioprosthetic aortic valves has not been established. A four-dimensional computed tomography (CT) imaging protocol to detect subclinical leaflet thrombosis was performed in over 900 patients with bioprosthetic valves at varying intervals after transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) . Subclinical leaflet thrombosis was more common with transcatheter valves than with surgical valves (13 versus 4 percent) and was more frequent with dual antiplatelet therapy compared with anticoagulation. Subclinical leaflet thrombosis was associated with an increased frequency of elevated aortic valve gradients and increased rates of transient ischemic attacks (TIAs) or strokes. Clinical trials are underway to determine the safety and efficacy of anticoagulation compared with the current standard of antiplatelet therapy following TAVI. (See "Transcatheter aortic valve implantation: Complications", section on 'Valve thrombosis'.)
Transcatheter aortic valve implantation versus surgical aortic valve replacement in patients at intermediate surgical risk (March 2017)
The role of transcatheter aortic valve implantation (TAVI) in patients with symptomatic severe aortic stenosis with intermediate surgical risk has not been established. A randomized trial in over 1700 patients compared outcomes following TAVI (with a self-expanding bioprosthesis; over 90 percent via transfemoral access) versus surgical aortic valve placement (SAVR) . The incidence of the primary composite end point of death from any cause or disabling stroke at 24 months was similar in the two groups. Rates of atrial fibrillation, transfusion, and acute kidney injury were more frequent in the SAVR group, while major vascular complications, permanent pacemaker implantation, and paravalvular aortic regurgitation were more common in the TAVI group. These results add to prior randomized trials showing that transfemoral TAVI is a noninferior alternative to SAVR in intermediate surgical risk patients with symptomatic severe aortic stenosis. (See "Choice of therapy for symptomatic severe aortic stenosis", section on 'In intermediate-risk patients'.)
Routine prophylactic antibiotics do not improve clinically important outcomes in survivors of out-of-hospital cardiac arrest (April 2017)
Many survivors of out-of-hospital cardiac arrest (OHCA) go on to develop pneumonia, but the value of prophylactic antibiotics is unproven. In a single-center clinical trial involving 60 comatose OHCA patients without obvious evidence of tracheobronchial aspiration on admission, random assignment to prophylactic antibiotics versus clinically-driven antibiotic therapy reduced the number of positive broncho-alveolar lavage cultures on hospital day 3, but did not improve survival or other patient-important outcomes . We do not suggest routine prophylactic treatment with antibiotics in these patients. (See "Post-cardiac arrest management in adults", section on 'Antibiotic therapy and prophylaxis'.)
Withholding ACE-I/ARB prior to noncardiac surgery (April 2017)
In many patients undergoing noncardiac surgery, angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) is withheld prior to the procedure out of a concern for the potential of perioperative hypotension. In a prospective cohort analysis of over 3000 patients undergoing noncardiac surgery taking these medications, the composite risk of all-cause death, stroke, or myocardial injury and the risk of intraoperative hypotension was lower among those in whom ACE-I/ARB was withheld . We omit these during the 24 hours prior to surgery in many patients. (See "Management of cardiac risk for noncardiac surgery", section on 'ACE inhibitor or ARB'.)
- Russo RJ, Costa HS, Silva PD, et al. Assessing the Risks Associated with MRI in Patients with a Pacemaker or Defibrillator. N Engl J Med 2017; 376:755.
- Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol 2017; 69:761.
- Millin MG, Comer AC, Nable JV, et al. Patients without ST elevation after return of spontaneous circulation may benefit from emergent percutaneous intervention: A systematic review and meta-analysis. Resuscitation 2016; 108:54.
- Antoniou T, Macdonald EM, Zhan Y et al. Association between statin use. CMAJ 2017; 189.
- Di Marco A, Anguera I, Schmitt M, et al. Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis. JACC Heart Fail 2016.
- Weng Z, Yao J, Chan RH, et al. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis. JACC Cardiovasc Imaging 2016; 9:1392.
- Brouwer TF, Yilmaz D, Lindeboom R, et al. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. J Am Coll Cardiol 2016; 68:2047.
- Kempny A, Hjortshøj CS, Gu H, et al. Predictors of Death in Contemporary Adult Patients With Eisenmenger Syndrome: A Multicenter Study. Circulation 2017; 135:1432.
- Taggart DP, Altman DG, Gray AM, et al. Randomized trial of bilateral versus single internal-thoracic-artery grafts. N Engl J Med 2016.
- Rossini R, Iorio A, Pozzi R, et al. Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). Circ Cardiovasc Interv 2017; 10.
- Li XS, Obeid S, Klingenberg R, et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J 2017; 38:814.
- Smits PC, Abdel-Wahab M, Neumann FJ, et al. Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. N Engl J Med 2017; 376:1234.
- Elgendy IY, Mahmoud AN, Kumbhani DJ, et al. Complete or Culprit-Only Revascularization for Patients With Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis of Randomized Trials. JACC Cardiovasc Interv 2017; 10:315.
- Pourdjabbar A, Hibbert B, Chong AY, et al. A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study. Thromb Haemost 2017; 117:303.
- Bangalore S, Fayyad R, Laskey R, et al. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med 2017; 376:1332.
- Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016; 375:2423.
- Packer M, O'Connor C, McMurray JJV, et al. Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. N Engl J Med 2017; 376:1956.
- O'Connor CM, Whellan DJ, Fiuzat M, et al. Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial. J Am Coll Cardiol 2017; 69:1577.
- McQuade CN, Mizus M, Wald JW, et al. Brain-Type Natriuretic Peptide and Amino-Terminal Pro-Brain-Type Natriuretic Peptide Discharge Thresholds for Acute Decompensated Heart Failure: A Systematic Review. Ann Intern Med 2017; 166:180.
- Carubelli V, Lombardi C, Lazzarini V, et al. N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure. J Cardiovasc Med (Hagerstown) 2016; 17:828.
- Felker GM, Whellan DJ. Inpatient Management of Heart Failure: Are We Shooting at the Right Target? Ann Intern Med 2017; 166:223.
- Schürer S, Klingel K, Sandri M, et al. Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy. JACC Heart Fail 2017; 5:435.
- Hiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med 2017; 376:32.
- Mazari FA, Khan JA, Samuel N, et al. Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease. Br J Surg 2017; 104:76.
- Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med 2017; 376:1430.
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376:1713.
- Bangalore S, Fakheri R, Wandel S, et al. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ 2017; 356:j4.
- Ford I, Shah AS, Zhang R, et al. High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease. J Am Coll Cardiol 2016; 68:2719.
- Yang X, Li J, Hu D, et al. Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China). Circulation 2016; 134:1430.
- Götberg M, Christiansen EH, Gudmundsdottir IJ, et al. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med 2017; 376:1813.
- Davies JE, Sen S, Dehbi HM, et al. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med 2017; 376:1824.
- Wykrzykowska JJ, Kraak RP, Hofma SH, et al. Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. N Engl J Med 2017.
- Bagur R, Solo K, Alghofaili S, et al. Cerebral Embolic Protection Devices During Transcatheter Aortic Valve Implantation: Systematic Review and Meta-Analysis. Stroke 2017; 48:1306.
- Charkravarty T, Sondergaard L, Friedman J et. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet 2017; Epub ahead of print.
- Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2017; 376:1321.
- Ribaric SF, Turel M, Knafelj R, et al. Prophylactic versus clinically-driven antibiotics in comatose survivors of out-of-hospital cardiac arrest-A randomized pilot study. Resuscitation 2017; 111:103.
- Roshanov PS, Rochwerg B, Patel A, et al. Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort. Anesthesiology 2017; 126:16.